MedWatch

Zealand Pharma reports positive data from phase Ib trial

The candidate dapiglutide has been assessed both safe and well tolerated in humans and has several potential indications within gastrointestinal and metabolic diseases, reports Zealand Pharma.

Photo: Zealand Pharma / PR

Zealand Pharma has completed a small phase Ib study with the GLP1-GLP2 dual receptor agonist dapiglutide, it reports in a press release.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Extra data boosts Lundbeck's agitation case

Pharmaceutical firm Lundbeck has presented positive new data at a US conference as it seeks approval for its candidate Rexulti as a treatment for agitation in Alzheimer’s patients.

Further reading

Related articles

Latest news

See all jobs